Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice

With Flatiron, Roche is at the forefront of the emerging field of RWE. Roche Pharma President O’Day described how the company is using such data in the real world of regulation and reimbursement.

Touch the future,Interface technology, the future of user experience.

External or historical control arms are at the forefront of real-world use of real-world evidence (RWE) in regulatory decisions about efficacy. And Roche, having acquired Flatiron Health Inc. and its database of electronic health records, is at the head of the pack.

The company has already used external control arms generated from electronic health records (EHR) data in reimbursement negotiations for Alecensa and Tecentriq, and Roche Pharmaceuticals CEO DanielO’Day expressed

More from Clinical Trials

More from R&D